Scientific intelligence record
Experience 2.0
Endogenous neurohypophyseal nonapeptide / vasopressor medicine
Arginine vasopressin, also called argipressin or antidiuretic hormone, is an endogenous cyclic nonapeptide synthesized in hypothalamic neurons and released from the posterior pituitary. V1a-receptor activation constricts vascular smooth muscle, V2-receptor activation promotes renal water reabsorption through aquaporin-2 trafficking, and additional receptor signaling contributes to pituitary, hemostatic, and central effects. Pharmaceutical vasopressin is used in tightly defined clinical contexts, notably as an intravenous vasopressor for vasodilatory shock in the United States; endogenous physiology, diagnostic biomarkers, receptor antagonists, analogs, and investigational intranasal research must remain distinct.
Record status
Traceability partial
Last meaningful update: 9/20/2026
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
500 matching records · ranked 2026-09-18
Page 1 of 20
Europe PMC · 2026 · PMID 41984305 · DOI 10.1007/s11102-026-01671-z
human-observational
Europe PMC · 2026 · PMID 42605676 · DOI 10.1161/hypertensionaha.126.25708
synthesis
Europe PMC · 2026 · PMID 41882896 · DOI 10.2169/internalmedicine.6898-25
preclinical-animal
Europe PMC · 2026 · PMID 41633840 · DOI 10.1523/eneuro.0323-25.2025
preclinical-animal
Europe PMC · 2026 · PMID 42541085 · DOI 10.4103/gmit.gmit-d-25-00083
human-interventional
Europe PMC · 2026 · Source ID doi:10.64898/2026.03.02.708998 · DOI 10.64898/2026.03.02.708998
preclinical-animal
Europe PMC · 2026 · PMID 42555711 · DOI 10.1126/sciadv.aef4951
preclinical-animal
Europe PMC · 2026 · PMID 42284142 · DOI 10.1016/j.celrep.2026.117516
preclinical-animal
Europe PMC · 2026 · PMID 42229615 · DOI 10.1016/j.mce.2026.112835
synthesis
Europe PMC · 2026 · PMID 42702826 · DOI 10.1111/jne.70257
preclinical-animal
Europe PMC · 2026 · PMID 42367581 · DOI 10.1093/narmme/ugag032
preclinical-animal
Europe PMC · 2026 · PMID 42677919 · DOI 10.1530/erc-26-0090
preclinical-animal
Europe PMC · 2026 · PMID 41668460 · DOI 10.1210/endocr/bqag014
preclinical-animal
Europe PMC · 2026 · Source ID doi:10.64898/2026.08.06.743275 · DOI 10.64898/2026.08.06.743275
laboratory-mechanistic
Europe PMC · 2026 · PMID 42385925 · DOI 10.1016/j.cbpc.2026.110607
preclinical-animal
Europe PMC · 2026 · PMID 41691609 · DOI 10.1113/jp290650
contextual-unclassified
Europe PMC · 2026 · PMID 42559779 · DOI 10.1016/j.jaccas.2026.109654
human-observational
Europe PMC · 2026 · PMID 41498140 · DOI 10.1161/hypertensionaha.125.25247
preclinical-animal
Europe PMC · 2026 · PMID 41791640 · DOI 10.1016/j.pnpbp.2026.111657
contextual-unclassified
Europe PMC · 2026 · PMID 41875524 · DOI 10.1016/j.amjsurg.2026.116938
preclinical-animal
Europe PMC · 2026 · PMID 42319076 · DOI 10.4274/tjar.2026.252131
human-observational
Europe PMC · 2026 · PMID 32809568
contextual-unclassified
Europe PMC · 2026 · PMID 41363127 · DOI 10.1210/clinem/dgaf651
human-interventional
Europe PMC · 2026 · PMID 42657772 · DOI 10.1210/clinem/dgag347
preclinical-animal
Europe PMC · 2026 · PMID 42381844 · DOI 10.4103/indianjpsychiatry_773_25
contextual-unclassified
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
Health Canada identifies a Canadian-authorized vasopressin injection product for intramuscular or subcutaneous administration in specified indications including postoperative abdominal distention, abdominal radiography, and diabetes insipidus; a March 4, 2026 communication also addresses temporary exceptional importation of a different U.S.-authorized IV product during shortage.
Health Canada — Importation of US-Authorized Vasopressin Injection during Canadian shortageVasopressin evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
APA
World Peptide Foundation. (n.d.). Vasopressin — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/vasopressin
AMA / Vancouver
World Peptide Foundation. Vasopressin — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/vasopressin
Ranked research corpus
500
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
500
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Vasopressin no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Diverse vascular effects have been ascribed to vasopressin, including the potential to cause vasodilation, vasoconstriction, and nitric oxide release.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
1975 · study · Temporal status not established
Gastroenterology
1984 · study · Temporal status not established
Hepatology (Baltimore, Md.)
1996 · study · Temporal status not established
Obstetrics and gynecology
2001 · study · Temporal status not established
Lancet (London, England)
2003 · study · Temporal status not established
Clinical pharmacology and therapeutics
2003 · study · Temporal status not established
The Annals of thoracic surgery
2006 · study · Temporal status not established
Critical care (London, England)
2006 · study · Temporal status not established
Intensive care medicine
2008 · study · Temporal status not established
The New England journal of medicine
2009 · study · Temporal status not established
American journal of respiratory and critical care medicine
2009 · study · Temporal status not established
Intensive care medicine
2010 · study · Temporal status not established
Intensive care medicine
2015 · study · Temporal status not established
Journal of cardiothoracic and vascular anesthesia
2015 · study · Temporal status not established
PloS one
2016 · study · Temporal status not established
JAMA
2017 · study · Temporal status not established
Anesthesiology
2017 · study · Temporal status not established
BJOG : an international journal of obstetrics and gynaecology
2018 · study · Temporal status not established
European journal of obstetrics, gynecology, and reproductive biology
2018 · study · Temporal status not established
Journal of cardiothoracic and vascular anesthesia
2019 · study · Temporal status not established
Critical care medicine
2019 · study · Temporal status not established
The Annals of thoracic surgery
2019 · study · Temporal status not established
Intensive care medicine
2023 · study · Temporal status not established
Shock (Augusta, Ga.)
2024 · study · Temporal status not established
Critical care (London, England)
2025 · study · Temporal status not established
Medicina intensiva
2026 · regulatory · Temporal status not established
Canada (Health Canada — Vasopressin Injection USP DIN 02139502)
2026 · regulatory · Temporal status not established
United States (FDA — VASOSTRICT)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
4 represented evidence records
Years represented: 2008, 2016, 2019
Publishing organizations appearing in records: Critical care medicine, Intensive care medicine, JAMA, The New England journal of medicine
3 represented evidence records
Years represented: 2006, 2010, 2018
Publishing organizations appearing in records: Critical care (London, England), Intensive care medicine, Journal of cardiothoracic and vascular anesthesia
2 represented evidence records
Years represented: 2019, 2024
Publishing organizations appearing in records: Critical care (London, England), Critical care medicine
2 represented evidence records
Years represented: 2016, 2019
Publishing organizations appearing in records: Intensive care medicine, JAMA
2 represented evidence records
Years represented: 2016, 2019
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Vasopressin evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
Canada (Health Canada — Vasopressin Injection USP DIN 02139502)
Regulator: Vasopressin Injection USP DIN 02139502)
As of: 9/10/2026 · Temporal status not established
Health Canada — Importation of US-Authorized Vasopressin Injection during Canadian shortage
United States (FDA — VASOSTRICT)
Regulator: VASOSTRICT)
As of: 9/10/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:33 AM
VASOSTRICT vasopressin intravenous solution is FDA-approved to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines, according to current labeling.
5 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To compare the effects of two arginine vasopressin (AVP) dose regimens on the hemodynamic response, catecholamine requirements, AVP plasma concentrations, organ function and adverse events in advanced vasodilatory shock.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Vasopressin has been proposed as a potent vasoactive agent in the treatment of vasodilatory shock in adults and children.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Survival rates for cardiac arrest patients, both in and out of hospital, are poor.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Vasopressin is commonly used as an adjunct to catecholamines to support blood pressure in refractory septic shock, but its effect on mortality is unknown.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Vasoplegic syndrome is a common complication after cardiac surgery and impacts negatively on patient outcomes.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Norepinephrine is currently recommended as the first-line vasopressor in septic shock; however, early vasopressin use has been proposed as an alternative.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Previous trials suggest that vasopressin may improve outcomes in patients with vasodilatory shock.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Evaluate the incidence of hypotension during the weaning phase of vasopressors.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Intraarterial vasopressin has been reported to be effective in the treatment of massive upper gastrointestinal hemorrhage.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To determine if higher-volume, fixed-dose administration of vasopressin further reduces blood loss at the time of minimally invasive myomectomy.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Arginine vasopressin is a nonapeptide hormone with effects on intracellular water transport and arterial tone that is used in distributive shock and following cardiopulmonary bypass.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To compare the efficacy and safety of intramyometrial vasopressin plus rectal misoprostol with intramyometrial vasopressin alone to reduce blood loss during laparoscopic myomectomy.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To assess the comparative efficacy of perivascular vasopressin and tourniquet in minimizing bleeding and its sequelae at myomectomy.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In a randomized controlled trial, the effect of continuous intravenous administration of vasopressin was compared with Sengstaken-Blakemore balloon tamponade in 37 episodes of bleeding esophageal varices in patients with cirrhosis.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The aim of this study was to investigate the relationship between intraoperative vasopressin infusion and postoperative cardiac enzymes.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Inhibition of angiotensin-converting enzyme (ACE) predisposes patients to vasodilatory hypotension after cardiopulmonary bypass (CPB).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To assess the safety of low-dose vasopressin infusion in critically ill children requiring prolonged mechanical ventilation (MV) at risk of developing sedation/analgesia-related hypotension.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Disturbances in microcirculatory homeostasis have been hypothesized to play a key role in the pathophysiology of multiple organ dysfunction syndrome and vasopressor-associated ischemic skin lesions.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To compare the effects of arginine-vasopressin (AVP) and norepinephrine (NE) on hemodynamic variables, organ dysfunction, and adverse events in early hyperdynamic septic shock.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To summarize the results of randomized controlled trials on the use of vasopressin as a vasopressor agent in cardiac surgery.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Background: Septic shock is a distributive shock with decreased systemic vascular resistance and MAP.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
International guidelines recommend dopamine or norepinephrine as first-line vasopressor agents in septic shock.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Excessive exposure to adrenergic vasopressors may be harmful.
We performed an individual patient data meta-analysis to investigate the possible benefits and harms of vasopressin therapy in adults with septic shock both overall and in pre-defined subgroups.
Publishing organizations appearing in records: Intensive care medicine, JAMA
2 represented evidence records
Years represented: 2016, 2019
Publishing organizations appearing in records: Intensive care medicine, JAMA
2 represented evidence records
Years represented: 2017, 2024
Publishing organizations appearing in records: Anesthesiology, Critical care (London, England)
2 represented evidence records
Years represented: 2006, 2010
Publishing organizations appearing in records: Critical care (London, England), Intensive care medicine
2 represented evidence records
Years represented: 2006, 2018
Publishing organizations appearing in records: Critical care (London, England), Journal of cardiothoracic and vascular anesthesia
2 represented evidence records
Years represented: 2006, 2018
Publishing organizations appearing in records: Critical care (London, England), Journal of cardiothoracic and vascular anesthesia
2 represented evidence records
Years represented: 2008, 2019
Publishing organizations appearing in records: Intensive care medicine, The New England journal of medicine
2 represented evidence records
Years represented: 2008, 2019
Publishing organizations appearing in records: Intensive care medicine, The New England journal of medicine